Year: 2024

Purpose Investments Inc. Announces Final November 2024 Distribution Rate for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund

Written by Customer Service on November 26, 2024. Posted in Dividend Reports And Estimates.

TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) — Purpose Investments Inc. announced today the final November 2024 distribution rates for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund. The following table reflects the final distribution amounts for the month of November. Ex-distribution date is November 27, 2024.Open-End Fund TickerSymbol Final distributionper unit Record Date Payable Date DistributionFrequencyPurpose USD CashManagement Fund –ETF Units MNU.U US $ 0.3833 11/27/2024 12/03/2024 MonthlyPurpose CashManagement Fund –ETF Units MNY $ 0.3214 11/27/2024 12/03/2024 MonthlyPurpose High InterestSavings Fund – ETFUnits PSA $ 0.1458 11/27/2024 12/03/2024 MonthlyPurpose US Cash Fund– ETF Units PSU.U US $ 0.3600 11/27/2024 12/03/2024 MonthlyAbout...

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Written by Customer Service on November 26, 2024. Posted in Public Companies.

STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference. About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering...

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

Written by Customer Service on November 26, 2024. Posted in Public Companies.

BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies,...

Air Freight Market is Poised to Achieve Worth of USD 162.39 Billion by 2031 | SkyQuest Technology

Written by Customer Service on November 26, 2024. Posted in Mergers And Acquisitions.

Westford USA, Nov. 26, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Air Freight Market size will attain a value of USD 162.39 Billion by 2031, with a CAGR of 10.3% over the forecast period (2024-2031). A combination of factors has driven rapid expansion in the air freight market in recent times. With the growth of the e-commerce industry, rapid and cross-border shipments have been emerging as a high-demand area. Air freight has become a source of critical supply chain destination due to the rapidly rising expectations of customers who seek expedited deliveries. Moreover, technological development has swept through changes in the air freight market. It interlinks blockchain, AI, and IoT to achieve better security, operation optimization, and visibility of the supply chain. All these technologies enable speedy customs processing...

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

Written by Customer Service on November 26, 2024. Posted in Earnings Releases And Operating Results.

EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cash Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway Conference Call Today, November 26 at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 26, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We made great headway toward our objectives this quarter, achieving a major milestone with NexoBrid approval for pediatric use in the U.S.,”...

The Joint Corp. to Participate in the 13th Annual ROTH Deer Valley Event

Written by Customer Service on November 26, 2024. Posted in Public Companies.

SCOTTSDALE, Ariz., Nov. 26, 2024 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, announced that management is scheduled to attend the 13th Annual ROTH Deer Valley Event on December 11-14, 2024. The conference is being held at the Montage Deer Valley in Park City, UT. President and Chief Executive Officer Sanjiv Razdan and Chief Financial Officer Jake Singleton will host one-on-one meetings on December 12th and 13th. Interested investors should contact their ROTH representative or Kirsten Chapman of Alliance Advisors IR at thejointinvestor@allianceadvisors.com. About The Joint Corp. (NASDAQ: JYNT)The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation’s...

Nkarta to Participate in an Upcoming Investor Conference

Written by Customer Service on November 26, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 7th Annual Evercore HealthCONx ConferenceDecember 4, 20242:10 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta...

Vacuum Cleaner Market is Predicted to Evolve at a Notable 9.7% CAGR through 2031 | SkyQuest Technology

Written by Customer Service on November 26, 2024. Posted in Mergers And Acquisitions.

Westford USA, Nov. 26, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Vacuum Cleaner Market. size will attain a value of USD 29.45 Billion by 2031, with a CAGR of 9.7% over the forecast period (2024-2031). Growing disposable income of people around the world and rising emphasis on cleanliness and hygiene are projected to primarily augment the vacuum cleaner market growth over the coming years. The development of robotic and automated vacuum cleaners is projected to offer new business opportunities for market players going forward. Download a detailed overview: https://www.skyquestt.com/sample-request/vacuum-cleaner-market Browse in-depth TOC on “Vacuum Cleaner Market”Pages – 165 Tables – 62 Figures – 75Vacuum Cleaner Market Overview:Report Coverage DetailsMarket Revenue in 2023 $ 12.8...

Hyperscale Data Announces a Special Dividend of Series F Exchangeable Preferred Stock

Written by Customer Service on November 26, 2024. Posted in Dividend Reports And Estimates.

All Common and Series C Convertible Preferred Stockholders to Receive Planned Dividend LAS VEGAS, Nov. 26, 2024 (GLOBE NEWSWIRE) — Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data,” or the “Company”), hereby announces that it plans to issue a special one-time dividend (the “Distribution”) of one million (1,000,000) shares of a newly designated Series F Exchangeable Preferred Stock (the “Series F Preferred Stock”) to all common stockholders and holders of the Series C Convertible Preferred Stock on an as-converted basis. The Company hereby announces that the record date for the Distribution has been set for December 13, 2024. Stockholders who own the Company’s stock at the close of trading on that date will be eligible to receive the shares of Series F Preferred Stock. Further, the Company...

Chronic Wound Care Market to Expand at a Modest 4.17% CAGR through 2031 | SkyQuest Technology

Written by Customer Service on November 26, 2024. Posted in Mergers And Acquisitions.

Chronic wounds are difficult to treat, with symptoms such as loss of skin tissue around the wound. Once a wound becomes chronic, medical intervention is necessary intensive care and chronic wound care products to heal the wound. Westford, USA, Nov. 26, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the chronic wound care market size will attain a value of USD 30.85 billion by 2031, with a CAGR of 4.17% over the forecast period (2024-2031). High prevalence of chronic diseases and advancements in wound care technologies are expected to drive chronic wound care market growth over in the future. Rising investments in wound care research are also expected to create new business scope for chronic wound care companies going forward. Request your free sample PDF of the report today: https://www.skyquestt.com/sample-request/chronic-wound-care-market Browse...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals